Welcome to our dedicated page for Strata Critical Medical SEC filings (Ticker: SRTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Strata Critical Medical, Inc. (Nasdaq: SRTA) provides access to the company’s regulatory disclosures as it executes its strategy in time-critical logistics and medical services for the U.S. healthcare industry. While no specific filings are listed here, Strata’s public communications reference documents such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which contain detailed financial statements, risk factors and management’s discussion of its organ logistics and medical services platform.
Through SEC filings, readers can review how Strata reports the performance of its air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion services, as well as perfusion staffing and equipment solutions offered under the Trinity Medical Solutions and Keystone Perfusion brands. The company also describes non-GAAP metrics like Adjusted EBITDA, Flight Profit, Flight Margin and various free cash flow measures, with reconciliations to GAAP figures typically presented in these filings or related materials.
Regulatory documents also summarize key corporate events that Strata highlights in its news releases, such as the divestiture of its Passenger business, the rebranding from Blade Air Mobility to Strata Critical Medical, the acquisition of Keystone Perfusion and the move to a single operating and reporting segment. Risk factor sections expand on themes the company mentions in press releases, including competition, reliance on transplant centers and organ procurement organizations, operational risks in organ transport and regulatory changes affecting its activities.
On Stock Titan, SEC filings for SRTA are supplemented with AI-powered summaries that explain complex sections in plain language, highlight important changes across reporting periods and help readers quickly identify disclosures related to organ logistics, medical services, acquisitions and non-GAAP performance measures. Real-time updates from EDGAR, combined with these summaries, make it easier to track how Strata’s regulatory reporting reflects its evolving business model in the U.S. healthcare and transplant ecosystem.
Strata Critical Medical, Inc. (SRTA) received an Amendment No. 3 to a Schedule 13G from Steele ExpCo Holdings, LLC, KSL Capital Partners V GP, LLC and Eric Charles Resnick reporting their ownership of Class A Common Stock. The reporting group beneficially owns 7,923,000 shares of Class A Common Stock, representing 9.0% of the class, based on 88,466,806 shares outstanding as of July 28, 2026. These shares are held directly by Steele ExpCo Holdings, LLC, with KSL Capital Partners V GP, LLC as its managing member and Eric Charles Resnick as managing member of that entity, so they may be deemed to share voting and dispositive power over these shares. The amendment notes that on May 7, 2026, 4,500,000 warrants to purchase Class A Common Stock held by Steele ExpCo Holdings, LLC expired in accordance with their terms.
Strata Critical Medical, Inc. director Reginald Love reported a sale of 5,091 shares of Class A common stock on August 10, 2026 at $5.75 per share in an open market or private transaction. Following this sale, he directly holds 146,481 shares of the company’s common stock.
Strata Critical Medical, Inc. generated revenue of $72,506 for the quarter and $139,890 for the six months ended June 30, 2026 (amounts in thousands), up from $45,108 and $81,056 a year earlier, reflecting growth in its Logistics segment and contributions from the newer Clinical segment.
Despite higher gross profit, net loss from continuing operations widened to $(10,516) for the quarter and $(8,114) year-to-date, compared with $(3,409) and $(5,021), driven in part by higher amortization of acquired intangibles and a $(5,510) loss from changes in fair value of assets and other liabilities. Cash and cash equivalents were $16,317 at June 30, 2026 versus $30,968 at year-end, while operating cash flow improved to $9,572 for the six months. During 2026 Strata completed three Clinical acquisitions with total consideration of $42,417, increasing goodwill to $106,946 and intangible assets to $60,008, and put in place a new $30.0 million asset-based revolving credit facility with no borrowings outstanding.
Strata Critical Medical, Inc. reported Q2 2026 revenue of $72.5 million, up 60.7% from Q2 2025, driven by 6.9% Logistics growth and the addition of Clinical services. Clinical revenue reached $24.3 million, up 22.6% sequentially, with Transplant Clinical up 27.3% and Other Clinical up 18.1% versus Q1 2026. Results reflect continuing operations after divesting the Passenger business.
Gross profit rose 68.9% to $15.2 million, lifting gross margin to 21.0%. Net loss from continuing operations widened to $10.5 million, or 14.5% of revenue, while Adjusted EBITDA increased to $7.9 million with a 10.9% margin. Operating cash flow was $5.7 million and Free Cash Flow was $2.9 million in Q2, with cash and cash equivalents of $16.3 million and short-term investments of $6.4 million at June 30, 2026. The company closed three bolt-on Clinical acquisitions and updated 2026 guidance to revenue of $285–295 million and Adjusted EBITDA of $33–35 million, both higher than prior ranges.
Cook William L. III reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. reported that director William L. Cook III received a grant of 44,438 Restricted Stock Units (RSUs) on July 30, 2026. The RSUs, granted at $0.0000 per share, will settle in Class A common stock when vested, with 100% vesting on the date of the company’s 2027 Annual Meeting of Stockholders. Following this award, Cook directly holds 97,671 shares of Class A common stock.
Love Reginald reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. reported that director Reginald Love received a grant of 37,675 Restricted Stock Units (RSUs) on July 30, 2026. The RSUs will be settled in Class A common stock and 100% vest on the date of the company's 2027 Annual Meeting of Stockholders. Following this equity award, Love's reported direct holdings total 151,572 shares of Class A common stock.
PHILIP EDWARD M reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. director Philip Edward M received a grant of 30,913 shares of Class A common stock on July 30, 2026, in the form of Restricted Stock Units. The RSUs will be settled in common shares and 100% vest on the date of the company’s 2027 Annual Meeting of Stockholders. Following this equity award, he holds 265,078 shares directly.
WIESENTHAL ROBERT S reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. reported that director Robert S. Wiesenthal received a grant of 50,234 Restricted Stock Units (RSUs) of Class A common stock on 2026-07-30. These RSUs will be settled in shares upon vesting, with 100% vesting on the date of the company’s 2027 Annual Meeting of Stockholders. Following this award, Wiesenthal holds 5,325,896 shares of Class A common stock. The award carries a stated price of $0.0000 per share, reflecting a non-cash equity grant.
LAUCK ANDREW reported acquisition or exercise transactions in this Form 4 filing.
Strata Critical Medical, Inc. reported that director Andrew Lauck received a grant of 35,260 Restricted Stock Units (RSUs) on 2026-07-30, which will settle in Class A common shares upon vesting. All RSUs vest on the date of the 2027 Annual Meeting of Stockholders. Following this award, Lauck's reported direct holdings are 170,902 shares.
Strata Critical Medical, Inc. reported that CEO, Logistics Scott M. Wunsch acquired 57,172 shares of Class A common stock on July 30, 2026 at no cost upon certification that performance criteria under previously granted PSUs were satisfied. On July 31, 2026, 13,992 shares were withheld at $5.09 per share to satisfy related tax obligations. In addition, 382,987 shares of Class A common stock are held indirectly through a limited liability company of which he is the sole member.